Has Sam Mathew received payments from drug or device companies?

Yes. Drug and device makers reported $2,618 in general payments to Sam Mathew across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sam Mathew did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sam Mathew come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sam Mathew

Physician Assistant · Dallas, TXNPI 1619198082

Payments from drug & device makers

$2,618in general payments, 2019–2025

Across 96 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$663
Astellas Pharma US Inc$478
Jazz Pharmaceuticals Inc.$114
Janssen Scientific Affairs, LLC$104
Amgen$100
Acrotech Biopharma Inc.$96
plus $1K from 32 others

What the payments were for

Food & beverage$1,88572%
Education$73428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	25	$663
Astellas Pharma US Inc	7	$478
Jazz Pharmaceuticals Inc.	5	$114
Janssen Scientific Affairs, LLC	4	$104
Amgen	1	$100
Acrotech Biopharma Inc.	4	$96
Merck	4	$87
Karyopharm Therapeutics Inc.	3	$76
Blueprint Medicines Corporation	3	$66
Rigel Pharmaceuticals, Inc.	4	$62
Legend Biotech USA Inc.	2	$47
Sanofi	2	$47
Morphosys, US Inc.	2	$47
GSK	2	$47
Dova Pharmaceuticals	2	$45
Novartis	2	$38
CTI Biopharma Corp.	2	$34
Taiho Oncology, Inc.	2	$32
Adaptive Biotechnologies Corporation	1	$30
AbbVie	1	$30
Pharmacyclics LLC, An Abbvie Company	1	$29
Stemline Therapeutics Inc.	1	$28
Ipsen Biopharmaceuticals, Inc	1	$25
Regeneron Healthcare Solutions, Inc.	1	$25
Syndax Pharmaceuticals, Inc.	1	$24
Exelixis Inc.	1	$24
Johnson & Johnson	1	$23
Servier Pharmaceuticals LLC	1	$22
ADC Therapeutics America, Inc.	1	$21
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
Sobi, Inc	1	$20
BTG International Inc.	1	$20
Menarini Silicon Biosystems, Inc.	1	$19
Sanofi-aventis U.S. LLC	1	$18
AstraZeneca	1	$18
Pfizer	1	$17
Epizyme, Inc.	1	$15
Iovance Biotherapeutics, Inc.	1	$6

How this compares

$2,618 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ValacyclovirValacyclovir Hcl	22	$514
Acyclovir	33	$299
Prochlorperazine Maleate	16	$150
Ondansetron Hcl	15	$117
Levofloxacin	11	$102

Paid to pharmacies, not to this prescriber.

Other physician assistant in Dallas

Cynthia TrickettDallas$1.3M
Michael WhiteDallas$276K
Sofia NeicherilDallas$62K
Shawn SommerladDallas$53K
Katherine TurnerDallas$43K
Tori BurnsDallas$39K
Suzanne RaczDallas$32K
Kristine KuceraMelissa$797K
Selina SantosAustin$543K
Matthew BrunoMcKinney$538K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →